Deafness associated with the use of Bortezomib in multiple myeloma

Acta Oncol. 2008;47(2):323-4. doi: 10.1080/02841860701558823.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Agents / adverse effects*
  • Boronic Acids / adverse effects*
  • Bortezomib
  • Fatal Outcome
  • Female
  • Hearing Loss, Sensorineural / chemically induced*
  • Humans
  • Immunoglobulin A / blood
  • Immunoglobulin A / drug effects
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / physiopathology
  • Pyrazines / adverse effects*
  • Risk Factors

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Immunoglobulin A
  • Pyrazines
  • Bortezomib